I'd love that now. If you bought higher and didn't average down, then not so much. What bothers me is some of these biotechs get snatched up so fast with nothing but preclinical compounds or sales less than a few million a year. Why hasn't anyone come to ARIA (and we hope mgt now will broadcast to the market a potential buyer unlike the last CEO) and offered anything short of BXLT who offered around $11 a share???? There are so many big pharmas and big bios that can do this in a heartbeat like some mentioned. If BIIB offered 3B a few weeks ago when they were 280-290 a share, they'd have ARIA drugs for nothing as their share price now is 240. They had to issue new shares at that price or sell some on the market when they were 280-290 a share to lock in the money but 3B for most of these firms is chump change. Either ARIA isn't worth 3B or they are getting attention and not telling us like before. I'd love to wake up this next Tuesday with a headlilne on CNBC saying ARIA to be bought out at $17.50 a share (or higher). NLOL
tanking big time. Geez, I looked at JUNO and as the close, it's worth (was worth) 4.3B bucks. They will have 50MM in sales for 2016 and maybe double that for 2017. I can't believe they were worth 4.3B and this POS is worth 1B or so on 4X sales. Denner, sell this junk at $15 immediately.
hope so. I'm tired of waiting. I do feel for the investors in JUNO. Been there and done that in ARIA that I bought at 20 a share and it hit the 2's. What gets me is there are maybe 50 companies who can buy this out but nobody has moved. Makes me scared that I'm wrong.